Pure Global
NCT06312787

A Study to Evaluate the Relative Bioavailability and Food Effect of a VX-118 Tablet Formulation

A Phase 1, Open-label, Randomized, Crossover Study to Evaluate the Relative Bioavailability and Food Effect of a Tablet Formulation of VX-118 in Healthy Adult Subjects
Vertex Pharmaceuticals Incorporated·Phase 1·ClinicalTrials.gov·drugRecruitment Completed
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Cystic Fibrosis
Drug/Device/Intervention
VX-118
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Vertex Pharmaceuticals Incorporated
Location
Lincoln, United States of America
Timeline & enrollment
Phase
Phase 1
Start date
Apr 02, 2024
End date
May 01, 2024
Enrollment
15 participants
Primary outcome

Maximum Observed Plasma Concentration (Cmax) of VX-118,Area Under the Concentration Versus Time Curve (AUC) of VX-118

Summary

The purpose of this study is to evaluate the relative bioavailability, effect of food on the
 pharmacokinetic parameters, and safety and tolerability, of a tablet formulation of VX-118 in
 healthy participants.

ICD-10 classifications
Cystic fibrosisCystic fibrosis, unspecifiedCystic fibrosis with other manifestationsCystic fibrosis with pulmonary manifestationsCystic fibrosis with intestinal manifestations
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06312787
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06312787 through Pure Global AI's free database. This Phase 1 trial is sponsored by Vertex Pharmaceuticals Incorporated and is currently Recruitment Completed. The study focuses on Cystic Fibrosis. Target enrollment is 15 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.